Merle-Béral H
Department of Hemato-immunology, Unité Claude-Bernard C20, Hôpital, Pitié-Salpêtrié, Paris, France.
Nouv Rev Fr Hematol (1978). 1990;32(5):319-21.
The CLL-B lymphocytes are characterized by the surface expression of B cell markers (CD19, CD20, HLA-DR) and of a low intensity IgM. The presence of T antigens (CD5, CD1) may be related either to the activation stage of these cells, either to their origin from a distinct B subset. In contrast, the detection of B5, CD25, CD71 and CD38 activation markers clearly demonstrated that the B-CLL lymphocyte is a preactivated or activated cell, at various phases of the cellular cycle. Functional studies revealed that B-CLL lymphocytes are susceptible to the effects of several interleukins (BCGF(s), IL2, IFN alpha). The inhibition of the response to IL2 by IL4 has important implications for the potential use of cytokines in the management of B-CLL patients.
慢性淋巴细胞白血病B淋巴细胞的特征是表面表达B细胞标志物（CD19、CD20、HLA-DR）以及低强度IgM。T抗原（CD5、CD1）的存在可能与这些细胞的激活阶段有关，也可能与它们源自不同的B细胞亚群有关。相比之下，B5、CD25、CD71和CD38激活标志物的检测清楚地表明，B-慢性淋巴细胞白血病淋巴细胞在细胞周期的各个阶段都是预激活或激活的细胞。功能研究表明，B-慢性淋巴细胞白血病淋巴细胞易受几种白细胞介素（BCGF(s)、IL2、IFNα）的影响。IL4对IL2反应的抑制对细胞因子在B-慢性淋巴细胞白血病患者治疗中的潜在应用具有重要意义。
